Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund I Inc GBP

Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund I Inc GBP
Polar Capital LLP
Open Ended Investment Company
1.16 %
Risk Rating
3 Year Sharpe
3 Year Alpha
0 %
MSCI World/Health Care NR USD
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies.
Holding %
Novartis AG 6.02 %
Medtronic PLC 5.16 %
Baxter International Inc 4.67 %
Bio-Rad Laboratories Inc 4.15 %
Novo Nordisk A/S B 3.76 %
Hill-Rom Holdings Inc 3.73 %
Boston Scientific Corp 3.61 %
Teleflex Inc 3.51 %
Edwards Lifesciences Corp 3.40 %
Quotient Ltd 3.27 %
Region %
United States 73.64 %
Europe - ex Euro 11.32 %
Eurozone 7.59 %
United Kingdom 5.37 %
Sector %
Healthcare 96.21 %
Polar Capital LLP
SW1E 5JD, London, United Kingdom
Legal Structure
Open Ended Investment Company


Daniel Mahony
Joined 12/03/2007

Daniel Mahony Ph.D. joined Polar Capital to establish the healthcare investment team in 2007. He is joint manager of the Healthcare Opportunities Fund and lead manager of the Healthcare Blue Chip Fund. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991.

Gareth Powell
Joined 12/03/2007

Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.